CD8A and cancer: Other studies have shown that most effects of monotherapy are additive in the context of combination therapy to facilitate the expansion of phenotypically deficient CD8 T cells converted to activated effector CD8 T cells [35], demonstrating the good prospect of PD-L1 in combination with other new checkpoints for cancer treatment.